Cariou, Bertrand

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 1,678

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 756

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 464

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology

Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 414

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 380

International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors

Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 379

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 336

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 296

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies

Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 172

High protein intake reduces intrahepatocellular lipid deposition in humans

Bortolotti, M., Kreis, R., Debard, C., Cariou, B., Faeh, D., Chetiveaux, M., Ith, M., Vermathen, P., Stefanoni, N., Lê, K.-A., et al. (2009) · The American Journal of Clinical Nutrition

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 146

Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial

Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 143

Inhibiting PCSK9 — biology beyond LDL control

Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 141

French Endocrine Society guidance on endocrine side effects of immunotherapy

Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 140

Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study

Cariou, B., Fontaine, P., Eschwege, E., Lièvre, M., Gouet, D., Huet, D., Madani, S., Lavigne, S., & Charbonnel, B. (2015) · Diabetes & Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 129

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab

Thedrez, A., Blom, D. J., Ramin-Mangata, S., Blanchard, V., Croyal, M., Chemello, K., Nativel, B., Pichelin, M., Cariou, B., Bourane, S., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 105

Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways

Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism

Cardiovascular Function and Risk FactorsDiabetes Treatment and Management

Cited by 81

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 72

PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer’s disease

Courtemanche, H., Bigot, E., Pichelin, M., Guyomarch, B., Boutoleau-Bretonnière, C., Le May, C., Derkinderen, P., & Cariou, B. (2018) · Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 39

Sotagliflozin as a potential treatment for type 2 diabetes mellitus

Cariou, B., & Charbonnel, B. (2015) · Expert Opinion on Investigational Drugs

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Colhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 33

PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol

Roubtsova, A., Garçon, D., Lacoste, S., Chamberland, A., Marcinkiewicz, J., Métivier, R., Sotin, T., Paquette, M., Bernard, S., Cariou, B., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 22

Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort

Wargny, M., Croyal, M., Ragot, S., Gand, E., Jacobi, D., Trochu, J.-N., Prieur, X., Le May, C., Goronflot, T., Cariou, B., et al. (2022) · Cardiovascular Diabetology

Heart Failure Treatment and ManagementNutritional Studies and Diet

Cited by 21